Drugs Targeting NTRK

  • Vitrakvi (larotrectinib) – approved for stage 4 NSCLC patients with a fusion in NTRK as detected by a biomarker test.
  • Rozlytrek (entrectinib) – approved for stage 4 NSCLC patients with a fusion in NTRK as detected by a biomarker test.